# A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke

> **NCT05445895** · PHASE4 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 483 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Renexin CR 200/160mg
- **DRUG:** Plavix 75mg

## Key facts

- **NCT ID:** NCT05445895
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-16
- **Primary completion:** 2025-10-02
- **Final completion:** 2025-11-07
- **Target enrollment:** 483 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445895, "A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05445895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*